The EMPRESS MI, DAPAPROTECTOR, and PRESTIGE-AMI trials, along with studies by Agban, Gutiérrez, and Li, are evaluating the impact of SGLT2 inhibitors on cardiac remodeling, NT-proBNP levels, and structural changes post-MI [45–49]. Here, SLC5A2 is linked to myocardial infarction.